We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Collaboration to Study Heart Disease and Diabetes Genes

By Biotechdaily staff writers
Posted on 23 Oct 2002
A scientific collaboration to study genes that may be useful in the diagnosis and treatment of cardiovascular disease and diabetes has been announced by Celera Diagnostics (Alameda, CA, USA) and Bristol-Myers Squibb (New York, NY, USA).

Under the terms of the agreement, Bristol-Myers Squibb will provide clinical samples and data to Celera Diagnostics, which will conduct studies to correlate genetic variability with cardiovascular disease and diabetes. More...
Bristol will receive exclusive rights to develop and market drugs for cardiovascular disease and diabetes based on therapeutic targets identified by the studies. Celera will retain exclusive rights to develop and market diagnostic products. The collaboration will be managed by a joint steering committee.

"This collaboration serves as a model of our approach to the discovery of markers and to the development of new diagnostic products that are actionable through their close association with therapeutic treatments,” said Kathy Ordonez, president of Celera Diagnostics.

The companies plan to analyze the genetic variation associated with 1,000 single nucleotide polymorphisms (SNPs) in more than 3,000 clinically defined samples. Bristol collected these samples for use in studies demonstrating efficacy of its cholesterol-lowering drugs in the treatment and prevention of coronary artery disease.





Related Links:
Bristol
Celera Diagnostics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Chromogenic Culture System
InTray™ COLOREX™ ECC
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.